# Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia

> **NCT06058572** · PHASE2 · RECRUITING · sponsor: **Tata Memorial Centre** · enrollment: 166 (estimated)

## Conditions studied

- Acute Leukemia

## Interventions

- **DRUG:** Rifaximin 200Mg Tab
- **PROCEDURE:** allogenic hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT06058572
- **Lead sponsor:** Tata Memorial Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-02
- **Primary completion:** 2027-08-02
- **Final completion:** 2027-08-02
- **Target enrollment:** 166 (ESTIMATED)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06058572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06058572, "Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06058572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*